Miguel Ferrer

Profesor Associat

Universitat Autònoma de Barcelona Facultat de Medicina

Spain

Research Interests

Explore related searches

Professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Professor Miguel Ferrer is an Associate Professor at the Universitat de Barcelona Facultat de Medicina in Spain. His research focuses on respiratory conditions, particularly pneumonia and acute respiratory distress syndrome, as demonstrated by his recent publications on treatment recommendations, risk factors, and outcomes related to these diseases. Additionally, he has contributed to studies assessing innovative therapies for severe respiratory infections, including the efficacy of trimodulin in COVID-19 patients.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (8)

SPAIN

View details

catia cilloniz

Associate Professor

University of Barcelona

SPAIN

View details

SARAH HEILI-FRADES

Chief Medical Officer Aether Tech SL

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Miguel Ferrer

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Impact of Empirical Treatment Recommendations From 2017 European Guidelines for Nosocomial Pneumonia

Risk factors and Outcomes related to Polymicrobial in Community-Acquired Pneumonia

Multidisciplinary Consensus on the Management of Non-Invasive Respiratory Support in the COVID-19 Patient

Association between Driving Pressure, Systemic Inflammation and Non-pulmonary Organ Dysfunction in Patients with Acute Respiratory Distress Syndrome, a Prospective Pathophysiological Study

Efficacy and safety of trimodulin in patients with severe COVID-19: results from a randomised, placebo-controlled, double-blind, multicentre, phase II trial (ESsCOVID)

Severe Community-Acquired Pneumonia: Noninvasive Mechanical Ventilation, Intubation, and HFNT

Bacterial Adaptive Memory in Methicillin-Resistant Staphylococcus aureus from Endotracheal Tubes

A long-lasting porcine model of ARDS caused by pneumonia and ventilator-induced lung injury

Ten Issues to Update in Nosocomial or Hospital-Acquired Pneumonia: An Expert Review

Machine-Learning Model for Mortality Prediction in Patients with Community-acquired Pneumonia: Development and validation study.

Early procalcitonin to predict mortality in critically ill COVID-19 patients: a multicentric cohort study.

Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study.

Impact of Cardiovascular Failure in Intensive Care Unit-Acquired Pneumonia: A Single-Center, Prospective Study

Characteristics and Outcomes in Patients with Ventilator-Associated Pneumonia Who Do or Do Not Develop Acute Respiratory Distress Syndrome. An Observational Study

Validation of a Prediction Score for Drug-resistant Microorganisms in Community-Acquired Pneumonia.

SARS-CoV-2–induced Acute Respiratory Distress Syndrome: Pulmonary Mechanics and Gas-Exchange Abnormalities

Diagnostic accuracy of gram staining when predicting staphylococcal hospital-acquired pneumonia and ventilator-associated pneumonia: a systematic review and meta-analysis.

Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS.

Collaborators (8)

Adrian Ceccato

Rafael Zaragoza

Alfredo Gea

Angel Estella

Jose L Del Pozo

Pablo Montero López

catia cilloniz

SARAH HEILI-FRADES

Make your next move.